Blog
RSS FeedPosted by Michael Wonder on 21 Sep 2025
KalVista Pharmaceuticals announces European Commission and Swissmedic approval of Ekterly (sebetralstat), first and only oral on-demand treatment for hereditary angioedema
19 September 2025 - First European launch of Ekterly expected in Germany Q4, 2025. ...
Posted by Michael Wonder on 21 Sep 2025
Idorsia’s Jeraygo (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
19 September 2025 - Jeraygo is a new oral antihypertensive therapy – the first systemic hypertension treatment to target a new ...
Posted by Michael Wonder on 11 Jul 2025
Swissmedic approves Ifinwil (eflornithine) for children diagnosed with high-risk neuroblastoma
8 July 2025 - Norgine is pleased to announce that Swissmedic has approved the registration of Ifinwil (eflornithine) as monotherapy ...
Posted by Michael Wonder on 27 Feb 2025
Swissmedic approves CSL Behring’s Andembry (garadacimab) for the prevention of recurrent attacks of hereditary angioedema
26 February 2025 - The approval marks the fifth regulatory approval of Andembry, reinforcing CSL’s decades long commitment to delivering ...
Posted by Michael Wonder on 19 Feb 2025
Galderma’s Nemluvio (nemolizumab) granted marketing authorisation in the United Kingdom and Switzerland for moderate to severe atopic dermatitis and prurigo nodularis
18 February 2025 - These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review ...
Posted by Michael Wonder on 15 Nov 2024
Leo Pharma’s Anzupgo (delgocitinib) cream achieves marketing approval in Switzerland
14 November 2024 - In addition to the results of the DELTA 1,2 and 3 trials, the marketing approval is supported ...
Posted by Michael Wonder on 18 Oct 2024
CSL Vifor and Travere Therapeutics announce SwissMedic approval of Filspari (sparsentan) for the treatment of IgA nephropathy
17 October 2024 - Temporary marketing authorisation is based on statistically significant and clinically meaningful results from the Phase 3 ...
Posted by Michael Wonder on 03 Aug 2024
Swissmedic authorises dengue fever vaccine
2 August 2024 - To date, no vaccine against dengue fever was authorised in Switzerland. ...
Posted by Michael Wonder on 28 Dec 2023
Swissmedic approves Beyfortus for RSV prophylaxis in newborns, infants and young children
28 December 2023 - Following a thorough review, Swissmedic has authorised the medicinal product Beyfortus from marketing authorisation holder Sanofi-Aventis (Suisse). ...
Posted by Michael Wonder on 12 Dec 2023
Orchard Therapeutics receives Swissmedic approval for Libmeldy in early-onset MLD
11 December 2023 - Orchard Therapeutics today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy (atidarsagene autotemcel), a ...
Posted by Michael Wonder on 03 Oct 2023
Swissmedic approves Moderna coronavirus vaccine Spikevax XBB.1.5
28 September 2023 - Spikevax XBB.1.5 approved for persons aged 18 and over ...
Posted by Michael Wonder on 21 Jun 2023
Akebia announces Swissmedic approval of Vafseo (vadadustat)
20 June 2023 - Akebia Therapeutics today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorisation ...
Posted by Michael Wonder on 09 Mar 2023
Swissmedic issues unlimited authorisation for booster dose of Moderna's bivalent COVID-19 Original/Omicron BA.4-5 vaccine
8 March 2023 - Spikevax bivalent Original/Omicron BA.4-5 mRNA vaccine authorised for people aged 18 and over. ...
Posted by Michael Wonder on 06 Dec 2022
Swissmedic approves Quviviq (daridorexant) – a first in class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning
5 December 2022 - Quviviq, Switzerland's first approved dual orexin receptor antagonist, offers a new targeted mechanism of action that decreases ...
Posted by Michael Wonder on 11 Oct 2022
Swiss drugs regulator approves one of Pfizer's COVID-19 booster shots
10 October 2022 - Swiss drugs regulator Swissmedic said on Monday it had temporarily approved Pfizer's COVID-19 booster shot targeting ...